MK6-83 is an agonist of the transient receptor potential channel ML3 (TRPML3). MK6-83 appears to be significantly more efficacious on fibroblast lysosomes isolated from R403C or V446L expressing cells than on those isolated from TRPML1-/- cells.
Traffic. 2022 May;23(5):238-269.
Current methods to analyze lysosome morphology, positioning, motility and function
MK6-83 purchased from AbMole
|Solubility (25°C)||DMSO 4 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Cheng-Chang Chen, et al. Nat Commun. A small molecule restores function to TRPML1 mutant isoforms responsible for mucolipidosis type IV
|Related TRP Channel Products|
4-(Phenyldiazenyl)benzoic acid is a photosensitive and photoswitchable TRPA1 agonist that can be used for the research of pain signaling.
Podocarpic acid is a natural product, which acts as a novel TRPA1 activator.
Vocacapsaicin (CA-008) hydrochloride, as a prodrug of capsaicin, is the first non-opioid TRPV1 agonist. Vocacapsaicin hydrochloride provides lasting pain relief.
Vocacapsaicin (CA-008), a prodrug of capsaicin, is the first (first-in-class) non-opioid TRPV1 agonist. Vocacapsaicin can provide lasting pain relief.
GDC-0334 is a TRPA1 antagonist for the treatment of TRPA1-mediated disease and is an oral candidate compound for the study of asthma.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.